US009408832B2

(12) **United States Patent**
Fernandez-Valle

(10) **Patent No.: US 9,408,832 B2**
(45) **Date of Patent: *Aug. 9, 2016**

(54) **LIM KINASEMODULATING AGENTS FOR NEUROFIBROMATOSES THERAPY AND METHODS FOR SCREENING FOR SAME**

(71) Applicant: **Cristina Fernandez-Valle**, Oviedo, FL (US)

(72) Inventor: **Cristina Fernandez-Valle**, Oviedo, FL (US)

(73) Assignee: **University of Central Florida Research Foundation, Inc.**, Orlando, FL (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

This patent is subject to a terminal disclaimer.

(21) Appl. No.: **14/385,211**

(22) PCT Filed: **Mar. 13, 2013**

(86) PCT No.: **PCT/US2013/030849**

§ 371 (c)(1),
(2) Date: **Sep. 15, 2014**

(87) PCT Pub. No.: **WO2013/138456**

PCT Pub. Date: **Sep. 19, 2013**

(65) **Prior Publication Data**

US 2015/0105441 A1 Apr. 16, 2015

Related U.S. Application Data

(60) Provisional application No. 61/610,744, filed on Mar. 14, 2012, provisional application No. 61/641,624, filed on May 2, 2012, provisional application No. 61/738,654, filed on Dec. 18, 2012.

(51) **Int. Cl.**

A61K 48/00	(2006.01)
C07H 21/02	(2006.01)
C07H 21/04	(2006.01)
A61K 31/427	(2006.01)
A61K 31/185	(2006.01)
A61K 31/38	(2006.01)
A61K 31/4709	(2006.01)
A61K 31/498	(2006.01)
A61K 31/55	(2006.01)
C12N 15/113	(2010.01)
G01N 33/50	(2006.01)
A61K 31/422	(2006.01)

(52) **U.S. Cl.**

CPC ***A61K 31/427*** (2013.01); ***A61K 31/185*** (2013.01); ***A61K 31/38*** (2013.01); ***A61K 31/422*** (2013.01); ***A61K 31/4709*** (2013.01); ***A61K 31/498*** (2013.01); ***A61K 31/55*** (2013.01); ***C12N 15/113*** (2013.01); ***C12N 15/1137*** (2013.01); ***C12Y 207/11001*** (2013.01); ***G01N 33/502*** (2013.01); ***G01N 33/5011*** (2013.01); ***G01N 33/5014*** (2013.01); ***G01N 33/5058*** (2013.01); *C12N 2310/11* (2013.01); *C12N 2310/12* (2013.01); *C12N 2310/14* (2013.01); *C12N 2310/141* (2013.01); *G01N 2333/912* (2013.01); *G01N 2500/04* (2013.01); *G01N 2500/10* (2013.01)

(58) **Field of Classification Search**

CPC A61K 48/00; C12N 15/111

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,010,175	A	4/1991	Rutter et al.
5,283,317	A	2/1994	Saifer et al.
5,288,514	A	2/1994	Ellman
5,506,337	A	4/1996	Summerton et al.
5,519,134	A	5/1996	Acevedo et al.
5,525,735	A	6/1996	Gallop et al.
5,539,083	A	7/1996	Cook et al.
5,549,974	A	8/1996	Holmes
5,569,588	A	10/1996	Ashby et al.
5,593,853	A	1/1997	Chen et al.
5,641,673	A	6/1997	Haseloff et al.
5,705,151	A	1/1998	Dow et al.
7,056,704	B2	6/2006	Tuschl et al.
7,078,196	B2	7/2006	Tuschl et al.
2004/0014047	A1	1/2004	Cowsert et al.
2004/0053411	A1	3/2004	Cullen et al.
2005/0075492	A1	4/2005	Chen et al.
2005/0277139	A1	12/2005	Bentwich et al.
2006/0110440	A1	5/2006	Glover et al.
2006/0130716	A1	6/2006	Reyes-taboada et al.
2006/0160764	A1	7/2006	Friedman et al.
2007/0009915	A1	1/2007	Wang
2007/0099193	A1	5/2007	Wang
2007/0099196	A1	5/2007	Kauppinen et al.
2011/0020816	A1	1/2011	Chen et al.
2011/0091510	A1	4/2011	Lele et al.
2011/0224286	A1	9/2011	Yu et al.
2011/0251255	A1	10/2011	Chakrabarti
2012/0034236	A1	2/2012	Chakrabarti

OTHER PUBLICATIONS

McConnell et al., "The Cytosensor Microphysiometer: Biological Applications of Silicon Technology", Science, 1992, vol. 257, pp. 1906-1912.

(Continued)

Primary Examiner — Amy Bowman

(74) *Attorney, Agent, or Firm* — Timothy H. Van Dyke; Beusse, Wolter, Sanks & Maire, PLLC

(57) **ABSTRACT**

Disclosed herein are methods of treating a patient at risk of developing or having a neurofibromatosis or a sporadic schwannoma. In exemplary embodiments, the method involves administering to a subject in need an effective amount of a LIMK modulating agent. Also disclosed are compounds newly identified to be inhibitors of Merlin-null Schwann cell proliferation and/or survival.

16 Claims, 10 Drawing Sheets